Yes that is correct, director purchased 500,000 shares.
The outstanding count is 17 million.
As a biotech company in the clinical trial phase there is little institutional interest.
Nasdaq lists 29 institutional owners holding 1.8 million shares.
Plenty of shares in circulation.
The current clinical trial Cassava is engaged in is a double blind trial, no one outside the data collectors has access to the info.
IMO this symbol is the plaything of an algo trading interest, and of course the requisite daytraders that accompany these no reason moves.
Short Interest on Dec 13 around 2.3 million shares.
When the algos move on, look out below.
News 
Market Data 
Discover 
